

Gompf's Antibiotics Redux

**A Pocket Tool for the Medical Student, or Resident on the
Infectious Diseases Clinical Rotation**

or

Just about anyone who could use a pocket antibiotic tool

By

**Sandra G. Gompf, MD
Professor, Infectious Diseases
University of South Florida
Morsani College of Medicine
Tampa, FL**

Updated JUL 2023



Gompf's Antibiotics Redux by Sandra G. Gompf, MD is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Made in the United States of America.

ANTIBIOTIC PEARLS

1. Penicillins generally cover Gram +s, anaerobes, certain Gram –s depending on the antibiotic.
2. Cephalosporins generally cover Gram +s (EXCEPT Enterococcus!), Gram –s, few or NO anaerobes. ONLY ceftazidime/cefepime/ceftolozane cover Pseudomonas..
3. Aztreonam, a monobactam, covers ONLY Gram –s, incl. Pseudomonas. Reserve for beta lactam-allergic patients.
4. Aminoglycosides generally cover Gram +s (except tobramycin) & Gram –s, NO anaerobes, some Mycobacteria. Increasing resistance. Best in combination with beta lactams unless uncomplicated cystitis/pyelonephritis, but most use is declining due to nephrotoxicity & dual beta lactam options.
5. Quinolones cover Gram –s best (except moxifloxacin/delafloxacin, which are “respiratory quinolones” most active against Gram +s & anaerobes), some Mycobacteria.
6. Trimethoprim/sulfamethoxazole (TMP/SMX) generally covers MSSA/MRSA, Nocardia, Listeria, Pneumocystis, most Gram –s except Pseudomonas. Probably OK for Streptococcus pyogenes/agalactiae cellulitis as well.
7. Clindamycin generally covers Gram +s, incl anaerobes except Clostridia, like anaerobic/microaerophilic Strep/Peptostrep, Actinomyces (better for infections above the diaphragm).
8. Metronidazole generally covers anaerobes like Bacteroides, Prevotella, Clostridia; +/-Peptostrep (better for infections below the diaphragm).
9. Carbapenems in general are very broad & among our “last line” beta lactams. Use sparingly. Ertapenem covers most organisms except Pseudomonas. Imipenem, meropenem, & doripenem include Pseudomonas. Resistance in one carbapenem doesn’t predict resistance in others.
10. A word about Enterococcus! Enterococcus in well-defined polymicrobial infections (cholecystitis, GI perforation, decubitus infections) tends to be somewhat of an opportunist & clears once source control is achieved, even if it spills into blood). Isolated Enterococcus faecalis/faecium bacteremia or hematogenous infection (septic arthritis, vertebral osteomyelitis, endocarditis, “community-acquired” bacteremia without an immediately source) should raise as much concern as Staphylococcus aureus. In that setting, even if reported as very ampicillin/penicillin-susceptible, and ampicillin is considered “drug of choice”, know that these organisms have *lower*-affinity penicillin-binding proteins than other Gram + cocci, and “tolerance” may also occur with intermittent dosing of ampicillin/penicillin, which should be considered bacterioSTATIC. Synergistic combination therapy is preferred for these infections, such as amp + gentamicin. Amp + ceftriaxone/ceftriaxone is increasingly preferred due to nephrotoxicity with gent & gent resistance. The combination of these beta lactams binds more PBPs than ampicillin alone & lowers the ampicillin MIC. In addition, know that vancomycin is bactericidal for most GPCs *except Enterococcus* (bacterioSTATIC).

Shameless plug:

Visit www.gompsidpearls.net for more regularly updated ID clinical tools & links I find useful in practice.
}



Do's & DON'Ts

1. **Don't use an antibiotic if you don't need to.**
 - **If a bacterial infection is not high in the differential and the patient is not clinically toxic, forgo antibiotics. They are poor antipyretics.**
2. **Persistent fevers require work-up, not more antibiotics.**

If you are treating with broad antibiotics and fevers persist, **stop them**; they aren't helping.

 - Look for undrained foci of infection/pus → drain it.
 - Look for non-infectious cause → treat it.
 - True FJO in a rapidly deteriorating patient may warrant empiric anti-TB therapy → Call ID.
3. **DO use an oral antibiotic when you can; use one narrow antibiotic when you can; stop antibiotics when you can.**
 - Antibiotics are not cheap; switch to PO when reasonable.
 - Two antibiotics don't always prevent resistance better than one, and neither do broad spectrum drugs. More drugs = more resistance.
 - But NEVER give Rifampin alone! Rapid high-level resistance occurs.
 - TB/Atypical mycobacteria: NEVER use 1 drug in active TB
 - DON'T treat viral infections (or noninfectious syndromes) with antibiotics beyond the point at which you have ruled out bacterial infection.
4. **Don't combine 2 of the same class of antibiotics (e.g. 2 beta lactams, 2 quinolones) unless you have data or your friendly neighborhood ID specialist to back it up. They may unpredictably antagonize, synergize, or double the adverse effects.** E.g. Clindamycin-rifampin combo dramatically reduces clindamycin serum concentration.
[\[https://doi.org/10.1016/j.jinf.2015.03.013\]](https://doi.org/10.1016/j.jinf.2015.03.013); <http://dx.doi.org/10.1684/ejd.2013.2213>
5. **Always monitor for antibiotic adverse effects.**
 - Antibiotics are a double-edged sword. Respect them.
 - Watch for hypersensitivity/bone marrow suppression/interstitial nephritis/hepatotoxicity/drug fever with beta lactams, acute tubular necrosis/irreversible ototoxicity with aminoglycosides, & Clostridium difficile with almost all of them.
 - Watch for yeast overgrowth/Candidemia with prolonged/multiple antibiotic therapy.
 - C. diff. is easy to miss in 2 situations:
 - Colostomies – stumps/small bowel can be infected with C.diff.!
 - Spinal cord injured patients – unexplained abdominal distension & leukocytosis are a clue
 - RIFAMPIN REDUCES EFFECTIVENESS OF ORAL CONTRACEPTIVES! Tell female patients to *add barrier contraception until the next new pill pack* after finishing antibiotics.

Antifungal coverage in general:

fluconazole = Cryptococcus, Coccidioides, dermatophytes, Candida EXCEPT Candida krusei/auris/some glabrata and all molds; high CSF/urine levels

itraconazole = Candida, Histo, Plasmodium, Crypto, Cocci, Aspergillus, Sporothrix, Paracocci, Talaromyces

voriconazole = Candida, Histo, Crypto, Aspergillus (except a few rare species, Fusarium, NOT initially for Mucor/Rhizopus, but OK as step-down after amphi B/source control; good CSF/poor urine levels

posaconazole = same as voriconazole, + Mucor/Rhizopus; variable CSF levels

isavuconazonium 372mg (= isavuconazole 200mg) = same as posaconazole, some Mucor, INFERIOR to caspofungin for candidemia; few drug interactions; poor CSF/urine levels

echinocandins (caspofungin/micafungin/anidulafungin) = Candida incl C. auris, Aspergillus, SOME Cryptococcus, NOT Fusarium/Mucor/Rhizopus/Trichosporon, NOT Histo/Blasto/Coccidioides; poor levels in CSF/urine/vitreous humor

amphotericin B = all, +/- Fusarium, NOT Candida lusitanae (variable)/guillermoidi/auris, NOT Scedosporium (Pseudallescheria), Lomentospora (Scedosporium); Aspergillus terreus

flucytosine (5-fluorocytosine) - increases penetration of above drugs, rapid resistance alone; good CSF/eye/urine levels

Fusarium: Vori 6mg/kg IV Q24H or 300mg PO x 1 d, then 4mg/kg/d IV or 200mg PO BID + Amphi B 1.2 mg/kg/d or ABLC 5mg/kg/d

Mucor: Amphi B 1.5mg/kg/d or liposomal amphi B or ABLC 5mg/kg/d + posaconazole/isavuconazole (active metabolite of isavuconazonium); NOT other azoles/enchinocandins

BacteriCIDAL vs. BacterioSTATIC

A consideration in choosing treatments for serious infection like severe sepsis, bacteremia, meningitis, pneumonia, endocarditis, neutropenic fever. A "cidal" drug kills quickly; a "static" drug slows or stops replication and/or toxic production. Whether it matters is somewhat controversial.

Beta lactams are CIDAL and penetrate tissues and inflamed meninges well. They are preferable in serious infection, including bacteremia, endovascular infection, CNS infection, and streptococcal cellulitis. Their microbial action is *time-dependent*, meaning that they are most effective the longer the concentration of drug in the affected site remains above the MIC of the bacteria. Thus, they can be dosed by *continuous or extended infusion*, which may also facilitate home & hemodialysis dosing. (UpToDate has a helpful chart; most drug databases like ePocrates, etc, don't offer alternative dosing recommendations.) Ceftazidime, cefepime, and ertapenem are stable enough to be given 3 times a week after hemodialysis. Ampicillin is stable at least 24 hrs for extended and continuous infusion.

Extended Spectrum Beta Lactamase (ESBL)-Producing Gram Negative Bacilli: It's complicated & evolving as fast as these organisms!

SPICE/SPACE/KEC are mnemonics for bacteria that either have *intrinsic* (chromosome-based, aka "constitutive") and/or *inducible* beta lactamases (chromosome- OR mobile genetic element/plasmid-mediated beta lactamases). **These organisms may all demonstrate resistance to commonly prescribed beta lactams and may require carbapenem* treatment.** In addition, *inducible* beta lactamases in KEC organisms may become reversibly de-repressed (or "switched on") upon 1- 7 days' exposure to a beta lactam and result in treatment failure.

TL/DR: If suspecting severe sepsis, use ceftolozane-taz, ceftaz-avibactam, meropenem, or piperacillin-taz if MIC <16mg/L**; otherwise, can deescalate to cefepime if MIC ≤ 1 mg/L if stabilized, off pressors, etc.

KEC – Grouped by Family Enterobacteriaceae with moderate-high risk of *inducible, chromosomal beta-lactamase (AmpC, Group C, cephalosporinase)*—**KNOW that these may trick you by testing S to ceftriaxone/ceftazidime, →R may be induced.** Inducible beta lactamases may become reversibly de-repressed (or "switched on") upon 1- 7 days' exposure to a beta lactam and result in treatment failure. Cefepime is a weak AmpC inducer and stands up to hydrolysis by AmpC β-lactamase, so is generally a good choice if the organism is susceptible.

[Aside: *Klebsiella pneumoniae* & some *E. coli* often acquire a non-inducible, plasmid-based Group A beta lactamase (TEM) with a narrow spectrum against ampicillin & 1st-gen cephalosporins. Just be aware that this pattern comes up often in susceptibility testing & does not confirm or rule out an inducible ESBL.]

Klebsiella aerogenes (formerly *Enterobacter*)
Enterobacter cloacae
Citrobacter freundii

SPACE/SPICE – Treat based on susceptibility report and severity. [These species' ampC mutations are *usually not inducible*, so these DO test R to ceftriaxone/ceftazidime, so *this mnemonic has fallen out of favor.*] **Consider:** Severity of infection (bacteremia, meningitis), high inoculum/source control (UTI/pyelonephritis vs endocarditis), presence of biofilm (infected device), & MICs to cefepime (≤ 1 mg/L) & piperacillin-tazobactam (≤ 16 mg/L)** can help guide whether to use cefepime, pip-taz, or a carbapenem. Quinolones (bactericidal), trimethoprim-sulfamethoxazole (TMP-SMX), tetracyclines, and aminoglycosides are options if susceptible.

Presence of **chromosomal** (“constitutive”, “intrinsic”) or **mobile genetic element-acquired** (plasmid-mediated) beta lactamases.

Serratia/*Salmonella*/*Shigella*

Proteus (non-*P. mirabilis*/"Indole +")/*Providencia*

Pseudomonas

Acinetobacter baumannii complex

Citrobacter species

Enterobacter complex

(*Yersinia enterocolitica* – not enough data)

E. coli and *Klebsiella* are the most common ESBL producers, so many labs screen those isolates if MIC for ceftazidime is ≥ 2 mg/L. Remember that ***Klebsiella*** almost all have a constitutive chromosome-based beta lactamase (usually SHV-1) & test R to ampicillin/ticarcillin.

*Note that carbapenems and the monobactam, aztreonam *are* beta lactams, as they *all* have a beta lactam ring. This may be confusing initially when you read about beta-lactam resistance and recommendations to use a beta lactam “versus” carbapenem; many articles gloss over this.

**[MERINO Trial 2018](#) suggested higher 30-day all-cause mortality with pip-taz vs meropenem, but [other trials](#) and [post-hoc analysis of MERINO](#) have suggested MIC > 16 mg/L to pip-taz is responsible for the difference. If MIC is low, piperacillin-tazo may be acceptable as “carbapenem-sparing” in infections with source control (e.g. pyelonephritis without obstruction). See also [Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-Lactamase Producing *Escherichia coli*](#), 2013; [Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study](#) 10/27/2020; [IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0](#), 3/31/2022.)

Carbapenem (CP) Resistant Gram Negative Bacilli:

(Carbapenem attached to the beta lactam ring is what preserves activity against ESBL.) Affects mainly ***Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* (CRAB)**. May possess intrinsic vs mobile genetic element carbapenemase-encoding genes that inactivate enzymes, induce efflux pumps or limit porin channels. Carbapenems are not necessarily interchangeable.

Antibiotics for Resistant Gram + Cocci

- Vancomycin, teichoplanin (Europe) cover all but vancomycin-resistant Gram +s.
- Vancomycin is bacterioSTATIC against Enterococcus.
- Dalbavancin, oritavancin, telavancin - same mechanism as vancomycin & susceptibility generally correlates with vancomycin susceptibility; they add VRE, VISA/VRSA coverage.
- Daptomycin is bacteriCIDAL for both MRSA and Enterococcus & penetrates biofilm.
- Linezolid & tigecycline are bacterioSTATIC, NOT a choice for bacteremia unless no other options are possible, and not as monotherapy, unless you can cite legitimate supportive data.

- Tigecycline is difficult to tolerate due to 20% nausea/vomiting & associated with higher mortality than comparators for FDA-approved indications in after-market review of pooled clinical trials.
- All but vancomycin are EXPENSIVE & generally reserved for vancomycin-resistant Gram +s.

Pseudomonas, Acinetobacter, Stenotrophomonas vs other GNR

- These species are not of the family Enterobacteriaceae & often affect patients whose microbiome has been altered by extensive antibiotic/healthcare exposure.
- Acinetobacter are intrinsically resistant to multiple antibiotics and may be variably susceptible to carbapenems (*susceptibility to one carbapenem does not predict susceptibility to another!*)
- Stenotrophomonas are intrinsically resistant to *carbapenems*; generally most susceptible to quinolones, sulfas, and tetracyclines.

Which antibiotics are bacterioSTATIC?

"In sepsis, restore **V**olume with a **L**iter of **ST**_{AT} **N**ML (normal) **S**aline."

Vancomycin in Enterococcus – cidal for all other GPCs

Linezolid/Lefamulin

Sulfas/trimethoprim (*combination* is cidal)

Tetracyclines/Tigecycline

Nitrofurantoin (cidal in cystitis if concentration > 2x MIC)

"**MLS** antibiotic group" – clindamycin, macrolides (Note: Streptogramins are bactericidal)

Everything else is bactericidal.

Note bene: Clindamycin & linezolid are best studied as *adjuncts* for Staph or Strep toxic shock, severe streptococcal cellulitis or suspected necrotizing infection; *halt protein synthesis*—stops production of toxins that mediate severe inflammation, necrosis, and toxic shock. Many Staphylococcus aureus strains carry *inducible* clindamycin resistance genes, so I suggest having susceptibilities available before relying on clindamycin alone for this pathogen (if your lab doesn't report inducible clindamycin resistance, check for erythromycin resistance--- *erm* mutation! ---as a clue). Other drugs whose mechanism of action is disruption of protein synthesis: doxycycline/minocycline/tigecycline.

What does the MIC mean & how do we use it?

The MIC is the lowest concentration of an antimicrobial agent that completely prevents visible growth of the test strain of an organism in culture. Each antibiotic will have a different MIC for each organism. The MIC value of an antibiotic must be compared with clinical outcomes for the disease caused by a given organism; in some cases, this is further drilled down to differentiate between clinical scenarios (e.g., meningitis vs UTI), and the pharmacokinetics of individual antimicrobials. This overview yields "*clinical breakpoints*" that define whether the strain is susceptible (S), susceptible dose dependent (SDD) or resistant (R) to the antibiotic. Clinical breakpoints are internationally reviewed & adjusted yearly according to expert consensus, epidemiology, and clinical literature by EUCAST (European Committee on Antimicrobial Susceptibility Testing), the American CLSI (Clinical and Laboratory Standards Institute), and further updated by the FDA (Food and Drug Administration). Fortunately, your friendly hospital Micro lab and their automated systems do a LOT of the interpretation work for you. If Micro says it's susceptible, it usually is—just beware of SPICE/CEK (♠). And vancomycin "MIC creep" with *S. aureus* bacteremia—as MIC "creeps" above 1, so does treatment failure. Etc, etc.

Pharmacokinetics & Pharmacodynamics (PK/PD)

Important determinants of antibiotic dosing for maximal effect include time-dependent vs concentration-dependent activity, volume of distribution/vd (obesity, serum albumin), and route of elimination (renal, hepatic [cytochrome P450 enzymes], GI).

Time-Dependent antibiotics depend on duration of time that free antibiotic levels remain in tissue above MIC, no post-antibiotic effect. Doses must be given at regular intervals to maintain activity. Low albumin levels may lower free antibiotic levels by allowing increased free antibiotic to be cleared before it gets into tissues (highly protein-bound antibiotics may need higher doses, esp with less susceptible organisms).

- All beta lactams, monobactam, carbapenems

Concentration-dependent antibiotics act by achieving a high initial concentration & have a persistent "post-antibiotic effect"—i.e. bacterial growth is inhibited or "stunned" for a long time even after concentrations are no longer above MIC. Allows for extended dose intervals. Low albumin levels may lower free antibiotic levels by allowing increased free antibiotic to be cleared before it gets into tissues. At higher doses, highly protein-bound antibiotics may maintain adequate serum concentration if enough free antibiotic is available; again, may need higher dose).

- Aminoglycosides
- Daptomycin
- Metronidazole
- Quinolones (mostly)

Combination of Time above MIC + Post-antibiotic Effect

- MLS group – macrolides, clindamycin, tetracyclines
- Linezolid
- Vancomycin – dosing is optimized by achieving certain concentration for certain period of time, or "area under the curve" (AUC) -based dosing




Table 1. Protein binding of antibacterials commonly used in critically ill patients and of antibacterials in development (all protein binding data have been adapted from Donnelly et al.^[20] and MIMS Australia^[21]). We have also included data on antifungal agents for the reader's reference

Highly bound (>70%)	Moderately bound (70–30%)	Minimally bound (<30%)
Amphotericin B (90%)	Azithromycin (7–51%)	Amikacin (0–11%)
Anidulafungin (>99%)	Aztreonam (60%)	Amoxicillin (17–20%)
Caspofungin (97%)	Cefotaxime (40%)	Ampicillin (15–25%)
Cefazolin (75–85%)	Cefuroxime (33–50%)	Ceftepime (16–19%)
Cefonicid (98%)	Cephalothin (55–75%)	Ceftazidime (17%)
Cefoperazone (90%)	Ciprofloxacin (20–40%)	Ceftazopriole (22%)
Cefoxitin (80–50%)	Clarithromycin (42–50%)	Cefpirome (9%)
Ceftriaxone (85–95%)	Chloramphenicol (60%)	Colistin (<10%)
Cлиндармысн (90% bound to α_1-acid glycoprotein)	Levofloxacin (50%)	Doripenem (8%)
Cloxacillin (94%)	Linezolid (31%)	Ethambutol (20–30%)
Dalbavancн (93%)	Moxifloxacin (30–50%)	Fluconazole (11–12%)
Daptomyсн (90–93%, 30% to α_1-acid glycoprotein)	Nitrofurantoin (40%)	Fosfomycin (0%)
Dicloxacillin (97%)	Benzytpenicillin [penicillin-G] (65%)	Gentamycin (<30%)
Doxycycline (93%)	Piperacillin (30%)	Imipenem (20%)
Ertapenem (85–95%)	Sulfamethoxazole (68%)	Isotrizamide (0–10%)
Erythromycin (73–81%)	Ticarcillin (55%)	Meropenem (29%)
Faropenem (96–99%)	Trimethoprim (45%)	Metronidazole (<20%)
Flucloxacillin (95%)	Vancomycin (90–60%)	Norfloxacin (10–15%)
Fusidic acid (95–97%)	Voriconazole (58%)	Polymyxin B (<10%)
Idaprim (93%)		Quinupristin/dalfopristin (11–26%)
Itraconazole (99.8%)		Tobramycin (<30%)
Lincomycin (80–90%)		
Minocycline (75%)		
Natcillin (80%)		
Oxacillin (93%)		
Posaconazole (<97%)		
Ritampicin [rifampin] (80%)		
Sulfisoxazole (92%)		
Teicoplanin (90–95%)		
Telavancin (92–94%)		
Tigecycline (71–89%)		

PO cefpodoxime (18-30%, 30% urine excreted in urine; UTI indication)
PO cefadroxil (20% & 90% excreted unchanged in urine; UTI indication)

Synergistic IV Antibiotic Combinations against Specific Pathogens

Rule #1 – Don't wing it! Synergy is not that common. Some combos may be antagonistic, so combine with care (i.e. Use only combos supported by good literature).

Cell wall active agents + cell wall active agents

- serious GPC/GNR infections
 - **Beta lactams + aminoglycosides**
 - Beta lactam increases cell wall penetration by AG→AG disrupts cell wall (superoxides) & cell wall protein production
- serious Enterococcus faecalis/faecium infections
 - **Ampicillin + cephalosporins/ertapenem**
 - binds more PBPs than ampicillin alone & lowers ampicillin MIC
 - now preferred to avoid nephrotoxicity of amp + gentamicin combo
- MSSA/MRSA persistent bacteremia/endocarditis salvage
 - **daptomycin + cephalosporins (esp ceftaroline)/ertapenem**
 -
 - **cefazolin/ceftarolin+ ertapenem** (meropenem can be safely used with ceftaro if SA & GNR infection!)
 - binds more PBPs
- KPC carbapenemase-producing GNR (bla_{KPC} mutation)
 - **ertapenem + meropenem**
 - erta acts as ("suicide antibiotic" preferential affinity for carbapenemase—erta resistance is often alerts Micro to test for KPC)
- Carbapenem-R Acinetobacter (CRAB)

- **Meropenem + sulbactam** (as ampicillin-sulbactam—high dose 6-9g/d for most effective sulbactam dose) or sulbactam-durlobactam)
- **Polymixin B or colistin + carbapenem, tigecycline, or amp-sulbactam** – more to come!

THE CLASSES (not an exhaustive list)

Penicillins – beta lactams are CIDAL, good tissue penetration

DRUG	COVERAGE	USES	TOXICITY	Cerebral Spinal Fluid (CSF)
<p>penicillin G</p> <p>§</p> <p>CIDAL</p>	<p>Group A Strep (no resistance)</p> <p>Strep viridans</p> <p>Neisseria</p> <p>Capnocytophagia</p> <p>Actinomyces</p> <p>Fusobacterium</p> <p>Clostridia perfringens/te-tani</p> <p>Pasteurella</p> <p>Treponema/</p> <p>Leptospirosis</p> <p>NOT Staph aureus (re-sistant)</p>	<p>Skin/soft tis-sue (SST) or mouth infec-tions</p>	<p>Hypersens-itivity</p> <p>Stevens</p> <p>Johnson</p> <p>Interstitial nephritis</p> <p>Seizures (if high level)</p> <p>Bone marrow suppress-ion</p> <p>C.difficile</p>	<p>YES if inflamed</p>
<p>AminoPCN</p> <p>\$\$</p> <p>amoxicillin*</p> <p>ampicillin*</p> <p>amox/clav</p> <p>amp/sulbactam</p> <p>CIDAL</p>	<p>Add to the above:</p> <p>Listeria</p> <p>MSSA</p> <p>Most Pneumococcus</p> <p>Proteus</p> <p>Hemophilus influ. (beta lactamase negative)</p> <p>Salmonella/Shigella</p> <p>Anaerobes</p> <p><i>* Klebsiella are intrinsi-cally resistant to amp/amox (clavula-nate/sulbactam don't add much activity)</i></p> <p>Note: High-dose amp-sulbactam may used as a source of <i>subactam</i> in treating MDR Acinetobacter</p>	<p>Otitis media</p> <p>Sinusitis</p> <p>SST</p> <p>Meningitis in elderly</p>	<p>Above</p>	
<p>CarboxyPCN</p> <p>\$\$</p> <p>ticarcillin/clav (Eu-ropes)</p> <p>piperacillin</p> <p>piperacillin/tazobac-tam</p> <p>CIDAL</p>	<p>Adds to the above:</p> <p>Pseudomonas</p> <p>Enterobacteriaceae*</p> <p>Stenotrophomonas (ticar)</p> <p>Gut anaerobes</p> <p>MSSA</p> <p>Pip & Pip/tazo more po-tent for GNRs & more resistant to AmpC/ESBLs (See "SPICE" above)</p> <p><i>*Klebsiella is intrinsically R to ticarcillin</i></p>	<p>Adds to above:</p> <p>Gut/ surgical infec-tions</p> <p>Nosocomial pneumonia</p> <p>Prostate</p> <p>Osteomyelitis</p>	<p>Above</p>	

Cephalosporins – Think of progressive broadening of spectrum from Gram + to Gram - with each generation. Beta lactams are CIDAL. [☉ = can be dosed 3 times weekly in dialysis patients] ***CROSS-ALLERGY (same side chains) between aztreonam – ceftazidime – cefiderocol***

DRUG	COVERAGE	USES	TOXICITY	CSF
1st Generation \$\$\$ cephalixin PO cefadroxil PO ceftazolin IV/IM ☹️ CICAL	GPC/MSSA/streptococci, E. coli, Proteus, some Klebsiella (increasingly ampC+/ESBL) NOT Enterococci	SSTI Uncomplicated/Non-diabetic osteomyelitis PreOP prophylaxis	Hypersensitivity Bone marrow suppression Diarrhea C.difficile	POOR
2nd Generation \$\$\$ cefuroxime (IV/PO) cefaclor (PO) Cefamycins: cefoxitin (IV) cefotetan (IV)	Streptococci, uncomplicated MSSA Pneumococcus Neisseria Some GNR except Pseudomonas Cefamycins are the only ones that reliably cover anaerobes NOT Enterococci	Community acquired pneumonia (CAP) meningitis OM/sinusitis Gonorrhea	Hypersensitivity RASH/Stevens Johnson w/ cefaclor High INR/PT w/ cefoxitin/cefotetan Bone marrow suppression C.difficile	YES if strongly inflamed -- ceftriaxone >90% protein bound, low BBB penetration
3rd Generation \$\$\$ Cefpodoxime (PO) ceftriaxone (IM/IV, QD dosing) cefotaxime (IV) CICAL	Above; covers viridans streptococci, pneumococcus, but reduced PBP binding in MSSA	Meningitis CAP Most community-acquired infections Gonorrhea Pyelonephritis Best <i>PO</i> cephalosporin for GU is cefpodoxime (20-30% protein-bound, vs <i>PO</i> cefdinir, which is poorly excreted in urine & up to 70% protein-bound)	Above Ceftriaxone: <i>Pseudo-cholelithiasis</i> (biliary sludge)	YES if strongly inflamed -- ceftriaxone >90% protein bound, low BBB penetration

<p>4th Generation/Anti-pseudomonal</p> <p>\$\$</p> <p>ceftazidime (IV) ☹️</p> <p>cefepime ☹️</p> <p>CIDAL</p>	<p>Above, plus Pseudomonas</p> <p>More resistant to beta lactamases/ESBLs (See "SPICE" above) because it is not porin-dependent</p> <p>NOT Enterococci</p>	<p>Above, plus neutropenic fever</p>	<p>Above</p> <p>Cefepime: <i>Encephalopathy</i>, non-convulsive status epilepticus</p>	
<p>5th Generation/Anti-MRSA</p> <p>\$\$\$</p> <p>ceftaroline</p> <p>CIDAL</p>	<p>Similar to 3rd generation, plus MRSA, VISA/VRSA/VRE faecalis (NOT E. faecium), pneumococcus, beta-lactamase + H.flu, Moraxella Listeria</p> <p>NO Pseudomonas</p>	<p>Complicated SSTI, CAP (NOT MRSA-insufficient data)</p>	<p>Above</p>	
<p>Advanced-generation/Anti-pseudomonal</p> <p>ceftolozane-tazobactam</p> <p>ceftazidime-avibactam</p> <p>CIDAL</p>	<p>Viridans streptococci NOT Enterococci or Staphylococci</p> <p>ceftoloz-taz covers GNRs incl Pseudomonas, ESBLs, <i>some</i> carbapenemase-producing P. aeruginosa (CRPA), NOT KPC+</p> <p>ceftaz-avi covers ESBL & KPC+ carbapenemase (1st line agent)</p> <p>ceftaz-avi covers GNRs incl Pseudomonas, adds coverage for ceftaz-R, ESBLs, <i>some</i> ampC-R, <i>some</i> carbapenemases (NOT metallobeta-lactamase)</p>	<p>Complicated UTI/pyelo</p> <p>Complicated intraabdominal infection</p> <p>ceftaz-avi adds HAP</p>	<p>Above</p> <p>Nausea, diarrhea, headache, fever, renal insufficiency (ceftolaz-taz)</p>	<p>ceftazidime - CSF: YES if inflamed (NOT avibactam) - 90% renal excretion, unchanged (avibactam 97%) - <10% protein bound</p> <p>ceftolozane - CSF UNKNOWN - > 95% renal excretion, unchanged - 87% protein bound</p>

<p>cefiderocol</p> <p>CIDAL</p> <p>Similar side chains of both cefep & ceftaz</p> <p>Trojan horse siderophore: Chelates Fe⁺⁺, so drug is actively transported with Fe⁺⁺ via siderophore channels</p>	<p>Reliably covers XDR/carbapenem-R: <i>Metallobetalactamase</i> producers (MBL)</p> <p>Klebsiella pneumoniae (KPC+)</p> <p>Pseudomonas aeruginosa (CRPA)</p> <p>Enterobacteriaceae (CRE)</p> <p>Acinetobacter baumannii (CRAB)</p> <p>Stenotrophomonas Burkholderia cepacia</p> <p>NO GPC!</p>	<p>Complicated UTI/pyelo</p> <p>HAP</p>	<p>Hypersensitivity</p> <p>Bone marrow suppression</p> <p>Diarrhea</p> <p>C.difficile</p> <p>Unclear if higher all-cause mortality in critically ill with carba-R GNB (CREDIBLE-CR trial)</p>	<p>-- CSF POOR</p> <p>-- 58% protein bound</p> <p>-- 60-70% renal excretion, unchanged</p>
--	---	---	---	--

Monobactam

DRUG	COVERAGE	USES	TOXICITY	CSF
aztreonam \$\$ CIDAL	ONLY GNRs, incl Pseudomonas Covers metallobetalactamase carbapenemases, but not ESBL (resistance usually occurs together)—combination of aztreonam + ceftazavibactam might be used in salvage cases (CID 2021;72:1871)	<u>GNR</u> infections; NOT a replacement for all aminoglycoside uses (no synergy for GPC, NO Enterococcal coverage)	Low Good alternative for beta lactam allergies EXCEPT with ceftazidime, cefiderocol	YES if inflamed [Modal J et al. AAC. 1986;29:281-3.]

Carbapenems (Reserved for Multidrug Resistant Organisms – MDRO)

[⊙ = can be dosed 3 times weekly in dialysis patients]

DRUG	COVERAGE	USES	TOXICITY	CSF
imipenem-cilastin meropenem meropenem-vaboractam imipenem-cilastin-relebactam \$\$\$	GPCs EXCEPT MRSA GNRs EXCEPT Stenotrophomonas/Burkholderia ESBL+ & "SPICE" GNRs Anaerobes (incl Cutibacterium) Listeria Pneumococcus Nocardia asteroides (NOT brasiliensis) Legionella Mycobacterium avium Enterococcus (NOT E. faecium) mero-vaboractam adds <i>carbapenemase+</i> <i>Klebsiella pneumonia</i> (KPC), class A carbap-R Enterobacteriaceae (NOT metalloβ-lactamase/OXA carbap-R, NOT carbap-R Pseudomonas/Acinetobacter) Relebactam is not active against Morganellaceae group (Morganella, Proteus, Providentia)	Resistant GNR infections Serious gut infections Necrotizing pancreatitis	IV/IM Hypersensitivity (~10% cross-allergy with β-lactams) Seizures with imipenem (if renal insufficiency or high levels used) Candida overgrowth/infections C.difficile	YES
doripenem \$\$\$ CIDAL	Above, possibly lower MICs to Pseudomonas & Acinetobacter	Above Higher mortality than imipenem in VAP	Above	
ertapenem ⊙ \$\$\$ CIDAL	Above, without Pseudomonas coverage	Postpartum uterine infections Postsurgical Abdominal infections (not Pseudomonas)	Above <i>Encephalopathy</i>	

Aminoglycosides

DRUG	COVERAGE	USES	TOXICITY/ MISC	CSF
gentamicin streptomycin spectinomycin tobramycin amikacin liposomal amikacin \$-\$\$\$ CIDAL	Gent: VSE/VRE/variable Staph, GNRs incl Pseudomonas Tobra/Amik: GNRs incl Pseudomonas Amik: TB, non-TB Mycobacteria Strepto -Yersinia -MDR Mtb Gent/Strepto -Tularemia Spectino -Gonorrhea NO coverage for: Acinetobacter/Stenotrophomonas Anaerobes Pneumococcus	Synergy with beta lactams for GPC/Pseudomonas infections Usually not used alone except for UTIs	IV/Aerosol Acute tubular necrosis (reversible) Cochlear toxicity (genetic predisposition) Vestibular toxicity (irreversible) When possible: -stop after 3-5 d -use once-daily dosing -avoid in elderly Liposomal amik – hypersensitivity pneumonitis, hemoptysis, bronchospasm, exacerbation of lung disease Neuromuscular blockade (may exacerbate myasthenia gravis & paralytic agents)	NO or UNKNOWN (use intrathecal)
fosfomycin \$\$ CIDAL	Enterococcus Staph. aureus GNRs	Simple cystitis in women Off-label q3days for complicated or MDR GNRs, VRE if susceptible	PO only Above, significant diarrhea	
plazomicin \$\$ CIDAL	GNRs incl MDR/KPC/metabolact/CRE GNRs, variable Pseudomonas (use only if known susceptible), NOT Steno, Acinetobacter	Complicated UTI/pyelo	IV only Above Limited data	

Sulfonamides/Sulfas (INTRACELLULAR ACTIVITY)

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
trimethoprim-sulfamethoxazole co-trimoxazole \$ STATIC for Staph	Staph. aureus (incl MRSA) (NOT <i>Enterococcus</i> , <i>Pseudomonas</i> , <i>Acinetobacter</i>) <i>Legionella</i> <i>Stenotrophomonas</i> <i>Listeria</i> <i>Pneumocystis</i> <i>Nocardia</i> Burkholderia cepacia Moraxella Yersinia Francisella tularensis <i>Toxoplasma</i> Atypical mycobacteria (<i>M. marinum</i>) Some common coliforms	UTI MRSA SSTI Specific agents at left	IV/PO RASH/Stevens Johnson Nausea Fever Bone marrow suppression Hemolysis (if G6PD deficient) Hepatotoxicity Elevated creatinine or K+ (competes with Cr for tubular secretion, blocks K+ excretion) Kernicterus in neonates C.difficile Sun sensitivity	YES

Pleuromutilins (INTRACELLULAR ACTIVITY)

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
Lefamulin** IV/PO Protein synthesis inhibitor – multiple binding sites to ribosome, higher resistance barrier STATIC	S. pneumoniae MSSA, ?MRSA Hemophilus influenzae Mycoplasma pneumoniae Chlamydia pneumoniae Legionella pneumophila	CAP/community-acquired pneumonia ** Bacteriostatic – be aware of this when empirically treating serious infections.	Nausea, hepatotoxicity, CNS Hypokalemia Prolonged QTc Teratogenicity C. difficile	UNKNOWN 70% fecal excretion

Macrolides/Lincosamides (Macrolide-Lincosamide-Streptogramin B class, or MSL—all bind 50s ribosome subunit & share resistance genes)

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
Macrolides erythromycin clarithromycin azithromycin \$\$ STATIC	Pneumococcus IF local resistance is <25% MSStaph. aureus (not MRSA) Legionella Listeria Hemophilus Moraxella Mycoplasma <i>Pertussis</i> Neisseria mening- gitis Chlamydia/He- mophilus ducreyi Campylobacter Helicobacter pylori Salmonella/Shi- gella <i>Bartonella</i> Borrelia burgdor- pheri (<i>Lyme</i> dis- ease <i>Babesia microti</i> Actinomyces Atypical mycobac- teria	LRTI/ bronchitis Sinusitis Dental/ oral infections Atypical myco- bacteria (incl MAC prophylaxis in HIV)	IV/PO Nausea/ vomiting Abdominal cramps/ diarrhea (Lowest with Azithro) C.difficile Ototoxicity with chronic use Rare association with cardiovascu- lar mortality with QTc prolongation, low Mg ⁺⁺ /K ⁺ . Interactions: Ery/Clari induce P450! Neuromuscular blockade with Ery (may exacerbate myasthenia gravis & paralytic agents)	Adequate – better for Mycoplasma, Legionella, Chlamydia

<p><u>Lincosamides</u></p> <p>clindamycin</p> <p>\$\$</p> <p>STATIC</p>	<p>CIDAL for Group A streptococcus, MSStaph. aureus (MRSA, but watch for inducible <i>erm</i> resistance. Clue is resistance to erythromycin)</p> <p>Pneumococcus</p> <p>Inhibits toxic proteins in severe Strep A & S. aureus/necrotizing fasciitis.</p> <p>Oral anaerobes: Gram + such as Peptostrepto-coccus, Fusobacterium, Prevotella, Actinomyces, & Clostridial spp other than Clostridium difficile</p> <p>Gram – such as Bacteroides (may not cover in up to 25% of cases or strains with MIC >= 8 mcg/mL)</p> <p>Babesiosis</p>	<p>Severe SSTI, necrotizing fasciitis, MRSA</p> <p><i>“Infections above the diaphragm”</i></p> <p>Head and neck/dental infections</p> <p>Lung abscess/ aspiration pneumonia (<i>tip: no teeth = no anaerobes</i>)</p> <p>Bacterial vaginosis</p> <p>Babesiosis</p> <p>Toxoplasma in HIV</p>	<p>IV/PO C.difficile!! (>30% develop it on a week of clinda)</p> <p>Dysgeusia</p> <p>Rash, fever, eosinophilia Erythema multiforme</p> <p>Reversible neutropenia/thrombocytopenia</p> <p>Watch for hepatitis/obstructive jaundice, severe liver injury</p> <p>Neuromuscular blockade (may exacerbate myasthenia gravis & paralytic agents)</p>	<p>POOR except for Toxoplasmosis in HIV</p>
--	--	---	--	---

Nitrofuran

DRUG	COVERAGE	USES	TOXICITY/MISC	CNS
nitrofurantoin \$ CIDAL	GNRs EXCEPT Pseudomonas, Proteus, and Enterococcus incl susceptible VRE Multiple sites of action, inhibits synthesis of DNA, RNA, proteins, cell wall – higher resistance barrier than most antibiotics	Cystitis Susceptible ESBL GNRs ONLY reaches therapeutic level in URINE	PO only Nausea/vomiting C.difficile	NONE

Quinolones (Resistance is rising due to overuse; single-step mutation → resistance may arise while on therapy; INTRACELLULAR ACTIVITY; high concentration in bone, prostate, CSF)

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
<p>“Gram negative” Quinolones</p> <p>ciprofloxacin levofloxacin norfloxacin</p> <p>\$\$-\$\$</p> <p>CIDAL</p>	<p>GNRs including Pseudomonas</p> <p>Levo covers pneumococcus & Stenotrophomonas well</p> <p>“Atypical” pneumonia: Mycoplasma, Chlamydia, Moraxella</p> <p>Some mycobacteria/TB</p>	<p>UTI/GU infection Intraabdominal infections Endometritis</p> <p>Hospital-associated lung infections</p> <p>Levo best for acute sinusitis/ CAP</p> <p>Norflo: UTI only</p>	<p>IV/PO IV=PO (bioequivalent)</p> <p>Dizziness/CNS Diarrhea Hypo-/hyperglycemia Sun sensitivity</p> <p>May exacerbate myasthenia gravis & paralytic agents (inhibits GABA receptors)</p> <p>May prolong QTc (watch for palpitations/syncope; avoid if QTc > 500msec, cardiomyopathy)</p> <p>Rare spontaneous tendon rupture (watch for pain at tendon sites)</p> <p>*Aortic dissection association*</p> <p>C.difficile</p>	<p>YES, HIGH DOSE</p>
<p>“Gram positive or Respiratory” Quinolone</p> <p>moxifloxacin</p> <p>\$\$</p> <p>CIDAL</p>	<p>Pneumococcus, Streptococci, Staphylococcus (NOT MRSA) Legionella Gut anaerobes</p> <p>Atypical mycobac/TB</p>	<p>CAP/community-associated respiratory infections Acute sinusitis</p> <p>Intraabdominal infections SSTI</p>	<p>IV/PO IV=PO (bioequivalent)</p> <p>Above >60% liver excretion</p>	<p>UNKNOWN</p>
<p>“Gram positive or Respiratory” Quinolone</p> <p>delafloxacin</p> <p>\$\$</p> <p>CIDAL</p>	<p>Streptococci, Staphylococcus MRSA Pseudomonas Legionella Gut anaerobes</p> <p>Atypical mycobac/TB</p>	<p>SSTI CAP/community-associated respiratory infections</p>	<p>IV/PO IV=PO (bioequivalent)</p> <p>Above</p>	<p>UNKNOWN</p>

Nitroimidazole

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
metronidazole	Gram – anaerobes incl.	“Infections below the diaphragm”	IV/PO	YES

<p>\$\$</p> <p>CIDAL</p>	<p>Bacteroides fragilis and all Clostridia</p> <p>Entamoeba coli</p>	<p>Intraabdominal abscess, peritonitis, diverticulitis, etc</p> <p>Endometritis/ Bacterial vaginosis</p> <p>Clostridium difficile colitis</p> <p>Entamoeba liver abscess/ dysentery</p> <p>NOT to be given alone for lung abscess/ENT infections</p>	<p>Disulfiram-like reaction (vomiting) if ethanol consumed within 3 days of therapy</p> <p>Aseptic meningitis/ neuropathies, rare</p>	
--------------------------	--	--	---	--

Tetracyclines/Glycylcycline (INTRACELLULAR ACTIVITY)

DRUG	COVERAGE	USES	TOX-ICITY/MISC	CSF
<p><u>Tetracyclines</u></p> <p>Minocycline Doxycycline</p> <p>\$</p> <p>STATIC</p>	<p>MRSA/MSSA Pneumococcus, +/- GAS E. coli Legionella N. meningitidis Hemophilus Moraxella Mycoplasma Chlamydia Listeria Brucella Actinomyces Borrelia burgdorferi Rickettsia Vibrio Treponema Anaerobes: Fusobacterium, Cutibacterium, Peptostreptococcus, Clostridium, some Bacteroides fragilis/melanogenicus</p>	<p>Acne/rosacea SSTI CAP, esp under age 40 Dog/cat bite prophylaxis as alternative to amox/clav Tickborne diseases</p>	<p>IV/PO Discoloration of permanent teeth in children</p> <p>Esophageal ulcer</p> <p>Hepatotoxicity</p> <p>Pseudotumor cerebri, esp minocycline! (watch for headache)</p> <p>Sun sensitivity</p> <p>C.difficile</p> <p>Inhibit lipopolysaccharide-induced proinflammatory products</p>	<p>YES (neuroborreliosis, syphilis)</p>
<p><u>Glycylcycline</u></p> <p>tigecycline >>> \$\$</p> <p>eravacycline* omadacycline</p> <p>sarecycline (acne only)</p> <p>STATIC</p>	<p>Above, plus Staph. epidermidis Enterococci Corynebacterium N. gonorrhoea ESBL + E.coli/Klebs (NOT KPC) Stenotrophomonas Acinetobacter Salmonella B. fragilis/ anaerobes Clostridia incl. C.difficile</p> <p>NOT Pseudomonas, Burkholderia</p> <p>*eravacycline adds ESBL, carbap-R Acinetobacter</p>	<p>SSTI Intraabdominal infections CAP/HAP</p> <p>Severe C.difficile Y alveolar, soft tissue, bile/gut entry</p> <p>Poor bone/joint, CNS</p> <p>** Bacteriostatic – be aware of this when empirically treating serious infections. > Increased mortality vs. comparators in after-market review of pooled clinical trials, incl in FDA-approved indications.</p>	<p>IV only Above</p> <p>20% tige, 6.5% erava - nausea, vomiting</p> <p>Inhibit lipopolysaccharide-induced proinflammatory products</p> <p>*/** Ampicillin/ Amoxicillin CIDAL-preferred in VRE that is amp-susceptible.</p>	<p>UNKNOWN</p>

Glycopeptides, lipoglycopeptides

DRUG	COVERAGE	USES	TOXICITY/ MISC	CSF
vancomycin \$ CIDAL except STATIC for <i>Enterococci</i>	Gram + cocci except VRE/VRSA Most Gram + rods (but see below) Corynebacterium Listeria C.diff (only PO) Increasing vancomycin MICs > 1 assoc with treatment failures ("MIC creep") Intrinsic resistance in: Leuconostoc Lactobacillus Propionobacterium Pediococcus Erysipelothrix Clostridia(non-diff.)	SSTI due to MRSA HAP/CAP due to MRSA Infections due to VRE	Vanc IV≠PO – PO not absorbed from gut Vanc requires a central IV line , due to phlebitis (which may cause fevers, unnecessary antibiotics/cultures/increased lengths of stay...) "Red man syndrome" with vanc (histamine release) if infused too rapidly—infuse over 1-2 hours Leukopenia Thrombocytopenia Rare interstitial necrosis Ototoxicity (abrupt, irreversible, usually elderly) Rarely, DRESS	YES
dalbavancin \$\$\$	MSSA, MRSA, Group A, B streptococci, Strep anginosus group	SSTI, osteomyelitis/prosthetic joint infection, endocarditis, bloodstream infection 1500mg IV x1 OR 1000mg IV then 500mg in 7 days	Nausea, headache, diarrhea Hepatotoxicity "Red man syndrome" with vanc (histamine release) if infused too rapidly—infuse over 1-2 hours	
televancin \$\$\$	MSSA, MRSA/VISA/VRS A, Group A, B streptococci, Strep anginosus group, VSEnterococcus	SSTI HAPneumonia due to MRSA/VISA	N/V, foamy urine Nephrotoxicity QTc prolongation Mortality > with mod/sev renal impairment compared with vanco Possibly teratogenic—avoid in pregnancy unless maternal benefit exceeds fetal risk	

			<p>“Red man syndrome” with vanc (histamine release) if infused too rapidly—infuse over 1-2 hours</p> <p>Interferes with coag tests but not coagulation</p>	
<p>oritavancin</p> <p>\$\$\$</p> <p>CIDAL including <i>Enterococci</i></p>	<p>MSSA, MRSA, Group A, B, C streptococcus, Streptococcus anginosus group, VSEnterococcus</p>	<p>SSTI</p> <p>**FAILED for osteomyelitis**</p> <p>1200mg IV x1, over 3 hr</p>	<p>Headache, N/V</p> <p>“Red man syndrome” with vanc (histamine release) if infused too rapidly—infuse over 1-2 hours</p> <p>Hepatotoxicity</p> <p>Artificially prolong PT/INR for up to 12 hr (5.1); aPTT for up to 120 hours, and may prolong PT and INR for up to 12 hr and ACT for up to 24 hr—Use Factor Xa assay for coagulation testing</p> <p>Coadministration with warfarin may result in higher exposure of warfarin and increase risk for bleeding; monitor frequently for signs of bleeding</p>	

Cyclic Lipopeptides

DRUG	COVERAGE	USES	TOXICITY/ MISC	CSF
daptomycin \$\$\$\$ CIDAL	All Gram + cocci incl. Vanc-/Amp- resistant* Entero- coccus MRSA/VRSA	SSTI Bacteremia Osteomyelitis, Joint infections May be active in biofilms (which usu- ally inactivate anti- biotics)	IV only False Prothrombin Time prolongation Nausea/vomiting Rhabdomyolysis & associated renal in- sufficiency (weekly creatinine, CPK) Rare asthmatic pul- monary eosinophilia NOT for primary pneumonia because it is inactivated in al- veolar fluid, BUT seems effective in embolic lung infec- tion/septic emboli due to Gram +s, since the infection is more parenchymal. *ampicillin/ amoxicillin (CIDAL) preferred in VRE that is amp-suscepti- ble.	UN- KNOWN

Streptogramins

DRUG	COVER-AGE	USES	TOXICITY/ MISC	CSF
quinupristin- dalfopristin \$\$\$\$ CIDAL Discontin- ued by Pfizer 2022	Vanc-/Amp- resistant* En- teroco-ccus faecium MSSA Group A Strep NOT Enter- oco-ccus fae- calis or MRSA	SSTI/non-MRSA Bacteremia Endocarditis due to VRE faecium Extremely limited use.	IV only Needs central IV line due to frequent pain, phlebitis, fever >30+% Myalgias/ Arthralgias Nausea/ Vomiting/ Diarrhea *ampicillin/ amoxicillin (CIDAL) preferred in VRE that is amp-susceptible.	UNKNOWN

Oxazolidinone (INTRACELLULAR ACTIVITY)

DRUG	COVER-AGE	USES	TOXICITY/ MISC	CSF
linezolid \$\$\$\$ STATIC except CIDAL for strepto- cocci	All Gram + cocci incl. ** vanc-/amp-re- sistant* Entero- coccus MRSA/VRSA TB/Atypical my- cobacteria Binds 23S rRNA- blocks formation of 50s/70s ribo- somal initiation complex	SSTI MRSA HAP/CAP due to MRSA Osteomyelitis/ Joint infections (good bone pene- tration) **NOT for bacte- remia without a well-defined and removal or drain- ing focus, NOT for endovascular in- fections	IV=PO (<i>bioequiva- lent</i>) Nausea/ vomiting/ diarrhea Temporary tooth staining Headache Thrombocytopenia/ Neutropenia after 7 days Peripheral/ Optic neuropathies with extended use Lactic acidosis (nau- sea, fatigue) Serotonin syn- drome: Avoid high tyramine food/drink, SSRIs (> 100mg tyramine per meal). E.g. aged cheeses, dried/pro- cessed meats, etha- nol, sauerkraut, soy sauce, or yeast ex- tract/supplements, ferments ***/**ampicillin/amoxi- cillin (CIDAL) pre- ferred in VRE that is amp-susceptible. **Associated with treatment failure in bacteremia , incl line & endovascular in- fections.	GOOD Myriantheis et al. Serum and CSF concentrations of linezolid in neurosurgery patients. AAC 2016. 50(12): 3971-6.

<p>tedizolid</p> <p>\$\$\$\$</p> <p>STATIC</p>	<p>All Gram + cocci incl. ** VRE, Amp-resistant* Enterococcus, MRSA/VRSA</p> <p>Binds 50s ribosomal subunit</p>	<p>SSTI</p>	<p><i>IV=PO (bioequivalent)</i></p> <p>6 days tedizolid Qdaily = 10 days linezolid BID = higher lipid solubility/higher tissue levels</p> <p>Nausea/headache/diarrhea Lower thrombocytopenia than linezolid; similar neuropathic events; no longer term data</p> <p>Serotonin syndrome: Avoid high tyramine food/drink (> 100mg tyramine per meal). E.g. aged cheeses, dried/processed meats, ethanol, sauerkraut, soy sauce, or yeast extract/supplements, ferments</p>	<p>NO DATA – suspect similar to linezolid</p>
--	---	-------------	--	---

Colistin/Polymixin B (Reserved for multi-drug resistant organisms - MDRO)

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
colistin polymixin B colistimethate \$\$\$ CIDAL	Gram - including Pseudomonas, Aci- netobacter membrane disrup- tion, binds lipopoly- saccharide (LPS)/ Gram - endotoxin	Intraabdominal in- fections UTI/GU infections Pneumonia/ Hospital-associated respiratory infec- tions Potent anti-LPS binding/ neutralizing activity	IV/Aerosol 30% Nephrotoxi- city! Peripheral/ Optic neuropath- ies Neuromuscular blockade (may exacerbate my- asthenia gravis & paralytic agents)	YES

Rifamycins

DRUG	COVERAGE	USES	TOXICITY/MISC	CSF
rifampin \$-\$\$ Only rifampin is discussed here, in context of use outside of mycobacterial infections CIDAL	Very broad, incl GPC/GNR, mycobacteria; use is <i>condition-specific</i> RAPID RESISTANCE if given alone – <i>Use in combinations</i> Inhibits DNA-dependent RNA polymerase	Only used alone as prophylaxis against <i>Neisseria meningitidis</i> (2 days), <i>Hemophilus influenza b</i> (4 days) in contacts/nasal carriage Combination treatment in serious <i>S. aureus</i> , Streptococcal infections Combination treatment of <i>Legionella</i> , Anthrax, <i>Brucella</i> , <i>Bartonella</i> , <i>Anaplasma</i> , <i>Ehrlichia</i> Combination treatment of tuberculous and non-tuberculous <i>Mycobacteria</i>	IV/PO Red urine, sweat, tears, saliva – hold soft contact use Nausea, abd pain Hepatotoxicity (avoid ethanol & hepatotoxins), hyper-bilirubinemia Type I & Flu-like hypersensitivity Autoimmune reactions Many drug interactions – always check an updated reference	YES

References:

<https://pubmed.ncbi.nlm.nih.gov/>

<http://webedition.sanfordguide.com/>

www.drugs.com

www.emedicine.medscape.com

www.epocrates.com

www.micromedix.com

Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011 Feb;50(2):99-110. doi: [10.2165/11539220-000000000-00000](https://doi.org/10.2165/11539220-000000000-00000). PMID: 21142293.

Acknowledgment:

Gratitude for support of my teaching efforts is owed to my alma mater, the University of South Florida Morsani College of Medicine Division of Infectious Diseases and International Medicine, and my distinguished professors there. I remain honored and very humbled to call them my colleagues these several years. I strive always to measure up to their high standards.

The opinions and information presented in any of my teaching materials, in print or electronically, remain my own intellectual property, and do not reflect the opinions or representations of any employer(s) or professional affiliates of which I am a part, past or present.

Thank YOU, dear Colleague, for your dedication to the Art and Science of Medicine. I hope that you find this tool of help in your care of the VIP at the center of our efforts:

The Patient.

Dr. G